High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results

M. Bruzzone, P. F. Conte, S. Chiara, F. Carnino, G. Giaccone, A. Conio, G. Bentivoglio, G. Pescetto, R. Rosso

Research output: Contribution to journalArticlepeer-review

Abstract

A substantial percentage of patients with advanced ovarian cancer will progress or relapse after platinum-based front therapies and will require salvage chemotherapy. In order to evaluate feasibility and effectiveness of high dose platinum (HD-CDDP) nine patients with ovarian cancer were treated with HD-CDDP while progressing after conventional doses of the same drug. Cisplatin 40 mg/M2 d. 1 → 5 q. 28 days, was administered with forced chloruresis for a total of fifteen cycles. Preliminary results show a promising 44.4% response rate with acceptable toxicity: only one patient had to discontinue treatment because of severe combined toxicity including infection, mucositis, shaking tremors, ototoxicity and palmar hyperkeratosis.

Original languageEnglish
Pages (from-to)139-142
Number of pages4
JournalChemioterapia
Volume4
Issue number2
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results'. Together they form a unique fingerprint.

Cite this